<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274326</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5816</org_study_id>
    <nct_id>NCT00274326</nct_id>
  </id_info>
  <brief_title>DILIPO (DILutIonal HyPOnatremia)</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary:

        -  To assess the efficacy of SR121463B in correcting hyponatremia in patients with
           dilutional hyponatremia other than SIADH or cirrhosis

      Secondary:

        -  To assess the long-term efficacy of SR121463B in maintaining normonatremia in these
           patients

        -  To assess the safety and tolerability of SR121463B
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SR121463B is an orally effective non-peptide, potent, and highly selective V2 receptor
      antagonist causing free water elimination in animals and humans
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EFFICACY:Serum Sodium</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>SAFETY:Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PHARMACOKINETICS:Plasma SR121463B concentrations</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight; EQ-5D and pharmaco-economic assessments</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR121463B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female patients aged 18 higher

          -  Dilutional Hyponatremia with serum sodium between 115 and 132 mmol/L

          -  Ability to give written informed consent (the informed consent may be signed by a
             legally authorized representative if the patient is unable to sign)

        Exclusion Criteria:

          -  Presence of known or untreated adrenal insufficiency, SIADH or cirrhosis, or
             hyperthyroidism

          -  Presence of signs of hypovolemia

          -  Administration of other V2 receptor antagonists or demeclocycline or lithium within
             one month and urea within two days prior to study drug administration

          -  Presence of uncontrolled diabetes with fasting glycemia ³ 200 mg/dL (³ 11.09 mmol/L)

          -  Patients considered by the Investigator unsuitable candidates to receive an
             investigational drug (e.g., presence of any neurological symptoms that may worsen in
             five days, based on the judgment of the Investigator, or presence of any neurological
             symptoms for which the persistence of hyponatremia over several days may be
             deleterious)

          -  Administration of inducers of CYP3A4 (phenobarbital, phenytoin, rifampin, Saint John's
             Wort) or potent and moderate inhibitors of CYP3A4 within two weeks prior to study drug
             administration

          -  Presence or history of allergic reaction to SR121463B8

          -  Previous study with SR121463B

          -  Inadequate hematological, renal, and hepatic functions: hemoglobin (Hb) &lt; 9 g/dL,
             neutrophils &lt; 1,500/mm3, platelets &lt; 100,000/mm3, serum creatinine &gt; 175 mol/L (or
             clearance of creatinine &lt; 30 mL/min for sites where Ethics Committees require this
             parameter), serum alanine aminotransferase (ALT) and/or aspartate aminotransferase
             (AST) &gt; 2 x upper limit of normal (ULN)

          -  QTCB 500 ³ ms

          -  Positive pregnancy test and absence of medically approved contraceptive methods (e.g.,
             surgical sterilization of more than one month duration, oral contraception or
             intrauterine device in combination with either diaphragm, condom, or spermicide) for
             females of childbearing potential

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Ter-Minassian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Australia &amp; New Zealand administrative office</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2006</study_first_submitted>
  <study_first_submitted_qc>January 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2006</study_first_posted>
  <last_update_submitted>September 12, 2008</last_update_submitted>
  <last_update_submitted_qc>September 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2008</last_update_posted>
  <keyword>Hyponatremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Satavaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

